“Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s119. doi:10.25251/skin.4.supp.119.